GO:0038127 ERBB signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0038127 (ERBB signaling pathway) describes the molecular signal cascade triggered when a ligand binds an ERBB family receptor tyrosine kinase (EGFR/ERBB1, ERBB2/HER2, ERBB3, ERBB4) on the cell surface, ending in regulation of downstream cellular processes such as transcription.
• The pathway is a central driver of proliferation, survival, migration and differentiation, and its dysregulation is a hallmark of many human cancers.
• ERBB receptors signal through RAS-MAPK, PI3K-AKT, PLCγ-PKC and STAT modules, and are modulated by cross-talk with other receptor systems such as IGF1R and GPCRs.
• Recurrent mutations and amplifications in ERBB pathway genes have been identified across tumor types, including gallbladder carcinoma and cervical cancer.
• The pathway is a validated therapeutic target, with multiple EGFR/ERBB inhibitors in clinical use or development.
• CRISPR-based knockout, point-mutation, knock-in and overexpression models enable causal dissection of ERBB signaling in disease and drug response.
Description
The ERBB signaling pathway (GO:0038127) is one of the most intensively studied receptor tyrosine kinase (RTK) networks in cell biology. It is initiated when an extracellular ligand, such as EGF or a neuregulin, binds to a member of the ERBB family of receptors on the plasma membrane, and it concludes with the regulation of downstream cellular processes including transcription. Because this pathway controls fundamental decisions about cell growth, survival and motility, it sits at the center of both normal tissue homeostasis and malignant transformation. For researchers, GO:0038127 provides a precise ontological anchor for annotating genes, interpreting omics data and designing mechanistic experiments. The pathway is also a paradigm for understanding how RTK signaling is amplified, diversified and integrated with other inputs, including G-protein-coupled receptor and IGF1R signaling. Its clinical relevance is underscored by the large number of approved and investigational drugs that target ERBB receptors and their downstream effectors.
ERBB signaling pathway At A Glance
| GO ID | GO:0038127 |
|---|---|
| GO term | ERBB signaling pathway |
| Ontology | biological_process |
| Synonym | EGF receptor family signaling pathway; EGFR family signaling pathway; ErbB signaling; ERBB signalling pathway |
| Definition | The series of molecular signals initiated by binding of a ligand to a member of the ERBB family of receptor tyrosine kinases on the surface of a cell, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| Major function | Transmits extracellular growth factor signals to control proliferation, survival, migration and differentiation. |
| Key receptors | EGFR (ERBB1), ERBB2 (HER2), ERBB3, ERBB4. |
| Major downstream modules | RAS-MAPK, PI3K-AKT, PLCγ-PKC, STAT. |
| Disease relevance | Dysregulated in multiple cancers and implicated in other proliferative disorders. |
What Is GO:0038127?
According to the Gene Ontology, GO:0038127 (ERBB signaling pathway) is defined as the series of molecular signals initiated by binding of a ligand to a member of the ERBB family of receptor tyrosine kinases on the surface of a cell, and ending with the regulation of a downstream cellular process, for example transcription. In practical terms, it encompasses ligand-induced receptor dimerization and activation, autophosphorylation, recruitment of adaptor and effector proteins, activation of intracellular kinase cascades, and the eventual modulation of gene expression or other cellular responses.
Why Is ERBB signaling pathway Important in Cell Biology?
GO:0038127 is important because ERBB signaling is a master regulator of cell fate and a frequent driver of human disease. Alterations in ERBB pathway components, including mutation, amplification and overexpression, are found in a wide range of cancers and contribute to tumor growth, survival and therapy resistance. The pathway also integrates inputs from other signaling systems, such as IGF1R and GPCRs, which further expands its regulatory influence. Because of its central role, the ERBB network is a major target for small-molecule inhibitors and antibodies, and it remains a focus for biomarker discovery and combination therapy. Understanding its mechanism at the level of individual genes and phosphorylation events is therefore essential for both basic and translational research.
• Controls fundamental cellular processes including proliferation, survival, migration and differentiation.
• Frequently mutated or amplified in human cancers, making it a key oncogenic driver.
• Serves as a validated target for approved and investigational therapeutics such as EGFR and HER2 inhibitors.
• Cross-talks with other receptor systems, including IGF1R and GPCR pathways, to modulate cellular responses.
• Provides a model system for studying receptor tyrosine kinase activation, dimerization and signal diversification.
• Is implicated in non-cancer contexts such as tissue repair and tendinopathy-related signaling.
• Its dysregulation can promote cervical cancer progression and other tumor types.
• Offers numerous nodes for CRISPR-based functional interrogation and drug-target validation.
What Happens During ERBB signaling pathway?
Ligand binding and receptor dimerization
In simple terms: A growth factor docks onto an ERBB receptor, causing two receptors to pair up.
The pathway begins when an extracellular ligand such as EGF binds to the ectodomain of an ERBB receptor. This binding induces a conformational change that promotes receptor dimerization, either as homodimers or heterodimers among EGFR, ERBB2, ERBB3 and ERBB4. Dimerization is a prerequisite for activation of the intracellular kinase domains and is a key point of regulation.
Receptor autophosphorylation and adaptor recruitment
In simple terms: The paired receptors add phosphate tags to each other, creating docking sites for partner proteins.
Upon dimerization, the intrinsic tyrosine kinase activity of the receptors is activated, leading to trans-autophosphorylation of specific tyrosine residues in the cytoplasmic tail. These phosphotyrosine motifs serve as docking sites for adaptor proteins and enzymes containing SH2 or PTB domains, thereby nucleating the formation of signaling complexes.
Activation of RAS-MAPK and PI3K-AKT cascades
In simple terms: The receptor relays the signal to two major internal highways that tell the cell to grow and survive.
Recruitment of GRB2 and SOS activates RAS, which in turn activates the RAF-MEK-ERK (MAPK) cascade to regulate transcription factors such as ELK1 and MYC. In parallel, recruitment of GAB1 or direct binding of PI3K leads to activation of AKT, which promotes survival and metabolism. These two modules are the principal downstream arms of ERBB signaling.
PLCγ-PKC and STAT signaling branches
In simple terms: Other branches of the pathway fine-tune the response and can alter gene expression.
Phospholipase C gamma (PLCγ) binds to activated ERBB receptors and hydrolyzes PIP2 to generate IP3 and DAG, leading to calcium release and PKC activation. In addition, ERBB receptors can activate STAT transcription factors, which translocate to the nucleus and regulate gene expression. These branches contribute to the diversity of cellular outcomes triggered by ERBB signaling.
Signal integration and cross-talk
In simple terms: The ERBB pathway does not act alone; it talks to other receptor systems to shape the final response.
ERBB signaling is modulated by extensive cross-talk with other pathways. For example, the P-Rex1/Rac module serves as a point of convergence for HER/ErbB receptor and GPCR responses, influencing cell migration. Similarly, cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor (IGF1R) pathway has been described in breast cancer, affecting downstream signaling and therapeutic response. This integration allows the cell to fine-tune its response to a complex environment.
Key Genes Involved in GO:0038127 ERBB signaling pathway
The following genes encode core components and regulators of the ERBB signaling pathway (GO:0038127) and are frequently studied in cancer and signaling research.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EGFR | Receptor tyrosine kinase that initiates the pathway upon ligand binding | Most studied ERBB receptor; target of multiple inhibitors |
| ERBB2 | Co-receptor that forms heterodimers and amplifies signaling | Amplified in breast and other cancers; target of trastuzumab |
| ERBB3 | Kinase-impaired receptor that partners with other ERBBs | Key activator of PI3K-AKT signaling |
| ERBB4 | Receptor that can signal as homodimer or heterodimer | Implicated in development and cancer |
| EGF | Ligand that binds EGFR and activates the pathway | Prototype ligand for pathway activation studies |
| NRG1 | Ligand for ERBB3/ERBB4 heterodimers | Important in neural and cardiac biology |
| GRB2 | Adaptor protein linking receptors to RAS-MAPK | Central node for downstream signaling |
| SOS1 | Guanine nucleotide exchange factor for RAS | Activates RAS upon recruitment |
| HRAS | Small GTPase that activates RAF-MEK-ERK | Frequently mutated in cancers |
| PIK3CA | Catalytic subunit of PI3K | Mutations drive AKT activation in cancer |
| AKT1 | Serine/threonine kinase mediating survival signals | Key effector of PI3K pathway |
| MAPK1 | Extracellular signal-regulated kinase 2 (ERK2) | Transmits signals to transcription factors |
| PLCG1 | Phospholipase C gamma 1 | Generates second messengers IP3 and DAG |
| STAT3 | Transcription factor activated by ERBB signaling | Regulates gene expression and tumor progression |
| P-Rex1 | Rac guanine nucleotide exchange factor | Convergence point for ERBB and GPCR signaling |
| IGF1R | Insulin-like growth factor 1 receptor | Cross-talks with ERBB family in breast cancer |
| CTHRC1 | Matricellular protein that enhances EGFR/MAPK signaling | Implicated in tendinopathy and tissue repair |
| NSUN7 | RNA methyltransferase that activates ErbB signaling | Promotes cervical cancer progression |
How Is ERBB signaling pathway Regulated?
ERBB signaling is tightly regulated at multiple levels. Receptor availability and activity are controlled by ligand abundance, negative feedback loops, and endocytic trafficking. Downstream, the pathway is modulated by phosphatases, such as PTPN and PTEN, which counteract kinase activity. Cross-talk with other signaling systems, including GPCRs via P-Rex1/Rac and IGF1R, provides additional layers of regulation. In cancer, dysregulation often occurs through mutation, amplification or autocrine ligand production, leading to constitutive pathway activation.
ERBB signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EGFR | Non-small cell lung cancer, glioblastoma | EGFR-mutant KO and point-mutation cell lines |
| ERBB2 | Breast cancer, gastric cancer | ERBB2-amplified overexpression models |
| ERBB3 | Breast and ovarian cancer | ERBB3 knockout and knock-in models |
| NSUN7 | Cervical cancer progression | NSUN7 overexpression and knockout cell lines |
| CTHRC1 | Tendinopathy | CTHRC1 knockout and overexpression models |
ERBB signaling in cancer
Dysregulated ERBB signaling is a hallmark of many human cancers. Activating mutations, gene amplifications and overexpression of EGFR, ERBB2 and other pathway components drive uncontrolled proliferation and survival. Whole-exome and targeted sequencing of gallbladder carcinoma identified recurrent mutations in the ErbB pathway, highlighting its role in this malignancy. In cervical cancer, NSUN7 promotes progression through activation of ErbB signaling, suggesting a regulatory axis that could be targeted. These findings underscore the importance of ERBB signaling as a therapeutic target and biomarker source.
ERBB signaling in non-cancer diseases
Beyond cancer, ERBB signaling is implicated in tissue repair and fibrotic conditions. For example, CTHRC1 attenuates tendinopathy by enhancing EGFR/MAPK signaling, indicating a protective role for this branch in tendon homeostasis. Cross-talk with IGF1R in breast cancer also illustrates how ERBB signaling integrates with other pathways in disease contexts. These observations broaden the relevance of GO:0038127 beyond oncology.
Therapeutic targeting of ERBB signaling
The clinical success of EGFR and HER2 inhibitors demonstrates the druggability of this pathway. However, resistance frequently emerges through secondary mutations, activation of bypass pathways, or cross-talk with other receptors such as IGF1R. Understanding these mechanisms is essential for developing next-generation inhibitors and combination strategies.
From ERBB signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of EGFR abolish ligand-induced MAPK activation? | EGFR knockout cell line |
| Does a specific point mutation in ERBB2 confer resistance to inhibitors? | ERBB2 point-mutation knock-in |
| Can a tagged ERBB3 reveal dynamic dimerization? | Tagged knock-in of ERBB3 |
| Does overexpression of NSUN7 activate ErbB signaling? | NSUN7 overexpression cell model |
| Does CTHRC1 enhance EGFR/MAPK signaling in tendon cells? | CTHRC1 knockout and overexpression |
| Does P-Rex1 mediate ERBB-GPCR cross-talk? | P-Rex1 knockout and rescue |
How to Study the ERBB signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptomic changes | Identify ERBB-driven gene expression programs |
| Phospho-proteomics | Phosphorylation status of signaling proteins | Map activated nodes after ligand stimulation |
| Western blot | Protein levels and phosphorylation of specific targets | Validate pathway activation and inhibitor effects |
| FRET biosensors | Real-time kinase activity and conformational changes | Study receptor dimerization dynamics |
| CRISPR knockout screens | Gene essentiality and pathway modifiers | Discover novel regulators of ERBB signaling |
| CRISPR activation screens | Gain-of-function phenotypes | Identify genes that enhance or bypass pathway inhibition |
| Immunoprecipitation-mass spectrometry | Protein-protein interactions | Map ERBB receptor interactomes |
| Flow cytometry | Cell surface receptor levels and apoptosis | Assess ERBB expression and drug response |
Transcriptomic and proteomic profiling
RNA-seq and mass spectrometry-based proteomics are widely used to capture global changes in gene and protein expression following ERBB pathway activation or inhibition. These methods can identify downstream transcriptional programs and phosphorylation events that define pathway output.
Phospho-specific signaling assays
Western blotting and phospho-antibody arrays are standard for measuring activation of key nodes such as phospho-EGFR, phospho-ERK and phospho-AKT. These assays provide quantitative readouts of pathway activity and are essential for validating inhibitor effects.
Live-cell imaging and FRET biosensors
Genetically encoded FRET biosensors and live-cell imaging allow real-time visualization of ERBB receptor dimerization, kinase activity and downstream signaling dynamics. These approaches reveal spatial and temporal features that bulk assays miss.
CRISPR-based functional screens
Pooled CRISPR knockout and activation screens can systematically identify genes that modulate ERBB signaling or confer resistance to targeted therapies. Such screens are powerful for discovering novel pathway components and therapeutic targets.
How CRISPR Can Be Used to Study GO:0038127 ERBB signaling pathway
Knockout
CRISPR knockout of ERBB pathway genes, such as EGFR or ERBB2, is used to determine their requirement for ligand-induced signaling and cellular phenotypes. Knockout cell lines provide clean genetic backgrounds for studying pathway rewiring and drug sensitivity.
Point Mutation
CRISPR-mediated point mutations can model clinically relevant activating or resistance mutations in ERBB receptors, such as EGFR L858R or T790M. These models are invaluable for testing next-generation inhibitors and understanding resistance mechanisms.
Knock-in
Knock-in of epitope tags or fluorescent proteins into endogenous ERBB loci enables real-time tracking of receptor localization, trafficking and interactions. This approach preserves native regulation and stoichiometry.
Overexpression
CRISPR activation or cDNA overexpression can model ERBB receptor amplification and ligand overproduction, mimicking oncogenic states. Overexpression models are useful for studying pathway addiction and identifying vulnerabilities.
How EDITGENE Supports ERBB signaling pathway Research
Researchers studying ERBB signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway activation, disease progression or drug response. Rigorous causal inference requires well-controlled genetic models that can isolate the contribution of a single gene or mutation. EDITGENE provides a comprehensive suite of CRISPR-based services to generate such models efficiently and reproducibly.
Contact EDITGENE today to design your custom CRISPR model for ERBB signaling pathway research.
Frequently Asked Questions About ERBB signaling pathway
What is the ERBB signaling pathway (GO:0038127)?
It is the series of molecular signals initiated by ligand binding to ERBB family receptor tyrosine kinases, leading to regulation of downstream cellular processes such as transcription.
What genes are involved in ERBB signaling pathway?
Core genes include EGFR, ERBB2, ERBB3, ERBB4, and downstream effectors such as GRB2, SOS1, HRAS, PIK3CA, AKT1, MAPK1, PLCG1 and STAT3.
What are the main downstream pathways of ERBB signaling?
The principal downstream modules are the RAS-MAPK and PI3K-AKT cascades, with additional branches through PLCγ-PKC and STAT.
How is ERBB signaling dysregulated in cancer?
Through activating mutations, gene amplification, overexpression or autocrine ligand production, leading to constitutive proliferation and survival signals.
What diseases are associated with ERBB signaling?
Many cancers, including lung, breast, gastric and gallbladder carcinoma, as well as non-cancer conditions such as tendinopathy.
What drugs target the ERBB signaling pathway?
Monoclonal antibodies and small-molecule tyrosine kinase inhibitors targeting EGFR and HER2 are approved for various cancers.
How can CRISPR be used to study ERBB signaling?
CRISPR knockout, point mutation, knock-in and overexpression models allow causal interrogation of individual pathway components.
What is the role of ERBB2 in the pathway?
ERBB2 is a co-receptor that forms heterodimers with other ERBB family members and amplifies downstream signaling.
Does ERBB signaling cross-talk with other pathways?
Yes, it cross-talks with GPCR signaling via P-Rex1/Rac and with IGF1R, among others.
What methods are used to study ERBB signaling?
Common methods include RNA-seq, phospho-proteomics, Western blotting, FRET biosensors and CRISPR screens.
Conclusion
GO:0038127 (ERBB signaling pathway) represents a central signaling network that translates extracellular cues into changes in gene expression and cell behavior. Its dysregulation is a major driver of cancer and other diseases, making it a prime target for therapeutic intervention. Continued research using advanced genetic models and multi-omics approaches will further clarify its mechanisms and identify new opportunities for precision medicine.
References
- 1. Levantini E et al.. 2022. EGFR signaling pathway as therapeutic target in human cancers.. Semin Cancer Biol 85:253-275 PMID: 35427766
- 2. Sabbah DA et al.. 2020. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.. Curr Top Med Chem 20(10):815-834 PMID: 32124699
- 3. Kazanietz MG et al.. 2018. The P-Rex1/Rac signaling pathway as a point of convergence for HER/ErbB receptor and GPCR responses.. Small GTPases 9(4):297-303 PMID: 27588611
- 4. Chen C et al.. 2024. CTHRC1 Attenuates Tendinopathy via Enhancing EGFR/MAPK Signaling Pathway.. Adv Sci (Weinh) 11(47):e2406611 PMID: 39540237
- 5. Jin Q et al.. 2008. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer.. J Mammary Gland Biol Neoplasia 13(4):485-98 PMID: 19034632
- 6. Iancu B et al.. 2019. Refinement-based modeling of the ErbB signaling pathway.. Comput Biol Med 106:91-96 PMID: 30708221
- 7. Li Y et al.. 2025. NSUN7 promotes cervical cancer progression through activation of ErbB signaling pathway.. Funct Integr Genomics 25(1):37 PMID: 39954044
- 8. Li M et al.. 2014. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.. Nat Genet 46(8):872-6 PMID: 24997986
